FDA affirms that traditional compounders must obtain patient-specific prescriptions, laying out the policy in a Sept. 15 letter responding to lawmakers' questions about whether the agency would allow compounding for physicians to use in their practice without having patient-specific prescriptions. Compounders worry the agency's stance against office-use compounding will prompt states to also restrict the practice, and hope lawmakers will change the policy through clarifying legislation as soon as possible. FDA's regulation of office-use compounding has been a highly watched...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.